Björklund Pharma

Advancing healthcare and wellness

  • Home
  • Company
  • Pipeline
  • Publications
  • Media
  • Contact

Joint and Bone Health

Product Candidate

Ostecibum

Osteoporosis is a prevalent bone metabolism disorder that can significantly impact the quality of life, especially in menopausal women. Addressing this concern, Ostecibum is a carefully formulated dietary supplement tailored to lower the risk of osteoporosis in menopausal women. Each capsule of Ostecibum contains essential ingredients known for their bone health benefits, including calcium citrate, vitamin D3, wild yam, and Chinese angelica root extracts.

The key components in Ostecibum play a crucial role in supporting bone health. Calcium citrate provides a readily absorbable form of calcium, essential for maintaining bone density and strength. Vitamin D3 aids calcium absorption, promoting bone mineralization and overall bone health. These two vital nutrients work synergistically to support bone density and reduce the risk of osteoporosis.

In addition to calcium and vitamin D3, Ostecibum includes root extracts of wild yam and Chinese angelica, both known for their beneficial effects on bone health. These herbal extracts contain natural compounds such as β-sitosterol, diosgenin, flavonoids, methoxy esters, and organic acids. These compounds have properties similar to estrogen and progestogen, effectively supporting bone health and alleviating menopausal symptoms.

While Ostecibum offers promising benefits for menopausal women seeking to lower their osteoporosis risk, certain contraindications should be considered. Individuals with allergies to any product components, lactating or pregnant women, those with estrogen-dependent malignant neoplasms, severe renal failure, or urolithiasis should refrain from using Ostecibum.

Related product
BasicMin Plus

Company News

  • New COVID-19 Research Provides Insights on the Crucial Role of Zinc in Protein Targets of Drugs That Block SARS-CoV-2 Infection
  • A Possible New Medicine for Multiple Sclerosis?
  • Thymosin Beta 4 in Dry Eye Syndrome
  • The Role of Thymosin Beta 4 in COVID-19 Treatment

Company News

  • New COVID-19 Research Provides Insights on the Crucial Role of Zinc in Protein Targets of Drugs That Block SARS-CoV-2 Infection
  • A Possible New Medicine for Multiple Sclerosis?
  • Thymosin Beta 4 in Dry Eye Syndrome
  • The Role of Thymosin Beta 4 in COVID-19 Treatment

Contact Us

Björklund Pharma AS
Toften 24
8610 Mo i Rana
Norway

Phone: +47 411 11 942
Email: info(at)bjorklundpharma.com

Copyright © 2025 Björklund Pharma AS